WHO and ECDC: 21 of 43 European Countries Show High Antibiotic Resistance in Hospital Bacteria
WHO and ECDC found half or more of K. pneumoniae samples resisted third-generation cephalosporins in 21 of 43 European countries reporting.
Half or more of hospital samples of two dangerous bacteria resisted key antibiotics in 21 of the countries reporting across Europe, according to a joint WHO and ECDC analysis.
Doctors, the report finds, are being pushed down a shrinking ladder of drugs — from standard antibiotics to carbapenems to a small group of last-resort medicines.
- In 21 of 43 reporting countries, at least half of Klebsiella pneumoniae samples resisted third-generation cephalosporins, or standard antibiotics.
- Carbapenem-resistant K. pneumoniae bloodstream infections rose by an estimated 72% between 2019 and 2025, against an EU target of a 5% fall.
- Only 40% of countries in the WHO European Region report carrying out their antimicrobial resistance action plans with funding and regular progress checks.
First-line drugs failing in half of Europe
The analysis, published with the European Centre for Disease Prevention and Control (ECDC), draws on 2025 data submitted by countries in the WHO European Region. It covers K. pneumoniae, a common hospital bacterium that can cause serious bloodstream infections, and Acinetobacter, which is also found in hospitals.
In 21 of the 43 countries that reported, half or more of K. pneumoniae samples were resistant to third-generation cephalosporins, or standard antibiotics. When those drugs fail, clinicians turn to carbapenems, antibiotics that work against a wider range of bacteria. In 10 reporting countries, half or more of K. pneumoniae samples resisted carbapenems too.
Acinetobacter shows a similar pattern. Half or more of samples resisted carbapenems in 21 of 38 reporting countries.
“In many countries in our Region, the antibiotics doctors usually reach for first are failing against serious hospital infections. So doctors turn to carbapenems, stronger drugs normally kept for the most serious cases. “When those stop working too, what’s left is mostly a small group of last-resort drugs that are often expensive and not available in every country,” said Dr Marc-Alain Widdowson, Programme Manager, Health Security Division, WHO/Europe.”
Widdowson also noted the clinical consequence: people whose first antibiotic does not work against their infection are more likely to die in hospital.
The gap between targets and 2025 reality
The EU set three 2030 targets in 2019 to cut bloodstream infections from resistant bacteria. Two have moved in the wrong direction. Carbapenem-resistant K. pneumoniae cases rose an estimated 75% between 2019 and 2025 against a target of a 5% fall. Third-generation cephalosporin-resistant E. coli, the most common cause of bloodstream infections in the EU, rose 16.4% against a target of a 10% reduction.
Carbapenem-resistant K. pneumoniae stood at 3.75 cases per 100,000 people in 2025, a 72% increase on the 2019 baseline. Cyprus recorded a 716% surge to 21.29 cases per 100,000 last year.
| Measure (2019–2025) | Change | 2030 target |
|---|---|---|
| Carbapenem-resistant K. pneumoniae bloodstream infections | +75% (EU estimate) | 5% fall |
| Third-gen cephalosporin-resistant E. coli bloodstream infections | +16.4% | 10% fall |
| MRSA bloodstream infections | −19% | 15% fall (met) |
| Human antibiotic consumption | −5% in 2025 vs 2019 | 20% fall by 2030 |
The MRSA target was met, with a 19% fall between 2019 and 2025. But infections have risen in the last two years, which may put that progress at risk. One brighter figure: estimated bloodstream infections with resistant Acinetobacter have fallen by almost 50% from the high levels seen in 2021 during the COVID-19 pandemic.
Where the outlets differ
The ECDC warned that more than 35,000 people die each year from antimicrobial resistance in the EU, Iceland, Liechtenstein and Norway — a toll the agency compares with the combined mortality of influenza, tuberculosis and HIV. The ECDC said that 90% of human antibiotic consumption occurs in the community or outpatient sector, and its 2026 campaign is focusing on children, who are often exposed to antibiotics.
“We are still behind with several of the EU’s 2030 targets to counter antimicrobial resistance. However, the good news is that we can now look beyond just numbers,” said Pamela Rendi-Wagner, ECDC Director.
Rendi-Wagner pointed to faster genomic surveillance as a reason for measured optimism, saying it allows health authorities to assess more rapidly how resistant bacteria spread and evade antibiotics, guide treatment decisions sooner, and identify where new antibiotics are most urgently needed.
Why resistance grows on the ward
Christian Giske, head of ECDC’s Antimicrobial Resistance and Healthcare-Associated Infections Section, said that healthcare-associated infections with multidrug-resistant bacteria — infections picked up by patients during hospital stays — account for over 70% of the health burden of antimicrobial resistance in Europe. He named good hand hygiene and vaccination, which reduce hospitalisation and antibiotic use overall, as front-line defences.
Among the ECDC’s priority measures at the point of care are dependable hand hygiene, proper use of personal protective equipment, prompt detection and isolation of affected patients, and thorough environmental cleaning and disinfection.
In 2026, the Centre released draft guidance on setting up and running IPC programmes in healthcare facilities and launched the hyFive digital tool to aid hand-hygiene monitoring and data-driven implementation. From 2024 to 2026, ECDC also carried out country visits in all Member States and gave tailored recommendations for AMR and healthcare-associated infections.
Plans on paper, money missing
Almost every country in the WHO European Region reports having a national action plan on antimicrobial resistance, or revising one. Only 40% report carrying it out with funding in place and regular checks on progress.
WHO/Europe is calling on countries to fund and execute those plans, treat hospital infection prevention as a priority, use antibiotics sparingly so carbapenems and last-resort drugs stay effective, invest in national reference laboratories that can identify carbapenem resistance mechanisms, collect more routine blood cultures before treatment, and guarantee access to last-resort antibiotics where needed.
“Nearly every country in our Region has a plan to tackle antimicrobial resistance. Far fewer have the money and follow-through to make it work, and a plan on paper doesn’t stop an infection on a hospital ward,” Widdowson said.
The full picture remains unclear: many countries still lack a standardised approach to collecting resistance data, and patients face risk from treatments that may not work.
The analysis was produced by the World Health Organization (WHO), a United Nations specialized agency founded on 7 April 1948 and headquartered in Geneva, Switzerland. It absorbed the League of Nations’ Health Organization and the Paris-based Office International d’Hygiène Publique, along with the International Classification of Diseases, and now operates through six regional offices and 150 field offices worldwide.
The agency, governed by the World Health Assembly and its 193 member states, is known for leading the eradication of smallpox and the near-eradication of polio, and it collects and publishes data on global health issues — a role central to surveillance efforts such as this report on antibiotic resistance.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.